World News | June 29, 2014
The latest set of opinions from advisors to the European Medicines Agency include recommendations to approve six new medicines, including Bristol-Myers Squibb’s new hepatitis C drug and Eli Lilly’s biosimilar of the Sanofi diabetes blockbuster Lantus.
Filed under: Biosimilar drugs Tagged: B-MS HCV drug, biosimilar, Bristol-Myers Squibb, CHMP, eli lilly, European Medicines Agency, hepatitis C drug, Kevin Grogan, Lilly Lantus
